Free Trial

Oramed Pharmaceuticals Q2 2023 Earnings Report

Oramed Pharmaceuticals logo
$2.46 0.00 (0.00%)
(As of 12/3/2024 ET)

Oramed Pharmaceuticals EPS Results

Actual EPS
-$0.03
Consensus EPS
-$0.11
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

Oramed Pharmaceuticals Revenue Results

Actual Revenue
$0.67 million
Expected Revenue
$0.70 million
Beat/Miss
Missed by -$30.00 thousand
YoY Revenue Growth
N/A

Oramed Pharmaceuticals Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

“Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

Oramed Pharmaceuticals Earnings Headlines

StockNews.com Downgrades Oramed Pharmaceuticals (NASDAQ:ORMP) to Sell
Coins Set to Soar with a Pro-Crypto White House
Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over $3 Million worth of crypto – and he's not the only one at the top interested in digital assets…
Oramed Pharm (ORMP) Receives a Hold from H.C. Wainwright
3 Micro-Cap Moonshots for Fearless Investors
See More Oramed Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oramed Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oramed Pharmaceuticals and other key companies, straight to your email.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

View Oramed Pharmaceuticals Profile

More Earnings Resources from MarketBeat